Loss of miR-204 expression is a key event in melanoma

Marco Galasso, Carl Morrison, Linda Minotti, Fabio Corrà, Carlotta Zerbinati, Chiara Agnoletto, Federica Baldassari, Matteo Fassan, Armando Bartolazzi, Andrea Vecchione, Gerard J. Nuovo, Gianpiero Di Leva, Stefania D'Atri, Ester Alvino, Maurizio Previati, Brian J. Nickoloff, Carlo M. Croce, Stefano Volinia

Research output: Contribution to journalLetter

6 Citations (Scopus)

Abstract

Cutaneous melanoma (CM) is a malignancy with increasing occurrence. Its microRNA repertoire has been defined in a number studies, leading to candidates for biological and clinical relevance: miR-200a/b/c, miR-203, miR-205, miR-204, miR-211, miR-23b and miR-26a/b. Our work was aimed to validate the role of these candidate miRNAs in melanoma, using additional patients cohorts and in vitro cultures. miR-26a, miR-204 and miR-211 were more expressed in normal melanocytes, while miR-23b, miR-200b/c, miR-203 and miR-205 in epidermis and keratinocytes. None of the keratinocyte-related miRNAs was associated with any known mutation or with clinical covariates in melanoma. On the other hand, the loss of miR-204 was enriched in melanomas with NRAS sole mutation (Fisher exact test, P = 0.001, Log Odds = 1.67), and less frequent than expected in those harbouring CDKN2A mutations (Fisher exact test, P = 0.001, Log Odds - 1.09). Additionally, miR-204 was associated with better prognosis in two independent melanoma cohorts and its exogenous expression led to growth impairment in melanoma cell lines. Thus, miR-204 represents a relevant mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in cooperation with NRAS.

Original languageEnglish
Article number71
JournalMolecular Cancer
Volume17
Issue number1
DOIs
Publication statusPublished - Mar 9 2018

Fingerprint

Melanoma
MicroRNAs
Keratinocytes
Mutation
Melanocytes
Epidermis
Cell Line
Skin
Growth
Neoplasms

Keywords

  • BRAF
  • Breslow
  • CDKN2A
  • Keratinocyte
  • Melanocyte
  • Melanoma
  • MicroRNA
  • Non coding rna
  • NRAS
  • Somatic alterations

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

Galasso, M., Morrison, C., Minotti, L., Corrà, F., Zerbinati, C., Agnoletto, C., ... Volinia, S. (2018). Loss of miR-204 expression is a key event in melanoma. Molecular Cancer, 17(1), [71]. https://doi.org/10.1186/s12943-018-0819-8

Loss of miR-204 expression is a key event in melanoma. / Galasso, Marco; Morrison, Carl; Minotti, Linda; Corrà, Fabio; Zerbinati, Carlotta; Agnoletto, Chiara; Baldassari, Federica; Fassan, Matteo; Bartolazzi, Armando; Vecchione, Andrea; Nuovo, Gerard J.; Di Leva, Gianpiero; D'Atri, Stefania; Alvino, Ester; Previati, Maurizio; Nickoloff, Brian J.; Croce, Carlo M.; Volinia, Stefano.

In: Molecular Cancer, Vol. 17, No. 1, 71, 09.03.2018.

Research output: Contribution to journalLetter

Galasso, M, Morrison, C, Minotti, L, Corrà, F, Zerbinati, C, Agnoletto, C, Baldassari, F, Fassan, M, Bartolazzi, A, Vecchione, A, Nuovo, GJ, Di Leva, G, D'Atri, S, Alvino, E, Previati, M, Nickoloff, BJ, Croce, CM & Volinia, S 2018, 'Loss of miR-204 expression is a key event in melanoma', Molecular Cancer, vol. 17, no. 1, 71. https://doi.org/10.1186/s12943-018-0819-8
Galasso M, Morrison C, Minotti L, Corrà F, Zerbinati C, Agnoletto C et al. Loss of miR-204 expression is a key event in melanoma. Molecular Cancer. 2018 Mar 9;17(1). 71. https://doi.org/10.1186/s12943-018-0819-8
Galasso, Marco ; Morrison, Carl ; Minotti, Linda ; Corrà, Fabio ; Zerbinati, Carlotta ; Agnoletto, Chiara ; Baldassari, Federica ; Fassan, Matteo ; Bartolazzi, Armando ; Vecchione, Andrea ; Nuovo, Gerard J. ; Di Leva, Gianpiero ; D'Atri, Stefania ; Alvino, Ester ; Previati, Maurizio ; Nickoloff, Brian J. ; Croce, Carlo M. ; Volinia, Stefano. / Loss of miR-204 expression is a key event in melanoma. In: Molecular Cancer. 2018 ; Vol. 17, No. 1.
@article{b17b9c4e90574101b375e33ebc567c7e,
title = "Loss of miR-204 expression is a key event in melanoma",
abstract = "Cutaneous melanoma (CM) is a malignancy with increasing occurrence. Its microRNA repertoire has been defined in a number studies, leading to candidates for biological and clinical relevance: miR-200a/b/c, miR-203, miR-205, miR-204, miR-211, miR-23b and miR-26a/b. Our work was aimed to validate the role of these candidate miRNAs in melanoma, using additional patients cohorts and in vitro cultures. miR-26a, miR-204 and miR-211 were more expressed in normal melanocytes, while miR-23b, miR-200b/c, miR-203 and miR-205 in epidermis and keratinocytes. None of the keratinocyte-related miRNAs was associated with any known mutation or with clinical covariates in melanoma. On the other hand, the loss of miR-204 was enriched in melanomas with NRAS sole mutation (Fisher exact test, P = 0.001, Log Odds = 1.67), and less frequent than expected in those harbouring CDKN2A mutations (Fisher exact test, P = 0.001, Log Odds - 1.09). Additionally, miR-204 was associated with better prognosis in two independent melanoma cohorts and its exogenous expression led to growth impairment in melanoma cell lines. Thus, miR-204 represents a relevant mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in cooperation with NRAS.",
keywords = "BRAF, Breslow, CDKN2A, Keratinocyte, Melanocyte, Melanoma, MicroRNA, Non coding rna, NRAS, Somatic alterations",
author = "Marco Galasso and Carl Morrison and Linda Minotti and Fabio Corr{\`a} and Carlotta Zerbinati and Chiara Agnoletto and Federica Baldassari and Matteo Fassan and Armando Bartolazzi and Andrea Vecchione and Nuovo, {Gerard J.} and {Di Leva}, Gianpiero and Stefania D'Atri and Ester Alvino and Maurizio Previati and Nickoloff, {Brian J.} and Croce, {Carlo M.} and Stefano Volinia",
year = "2018",
month = "3",
day = "9",
doi = "10.1186/s12943-018-0819-8",
language = "English",
volume = "17",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Loss of miR-204 expression is a key event in melanoma

AU - Galasso, Marco

AU - Morrison, Carl

AU - Minotti, Linda

AU - Corrà, Fabio

AU - Zerbinati, Carlotta

AU - Agnoletto, Chiara

AU - Baldassari, Federica

AU - Fassan, Matteo

AU - Bartolazzi, Armando

AU - Vecchione, Andrea

AU - Nuovo, Gerard J.

AU - Di Leva, Gianpiero

AU - D'Atri, Stefania

AU - Alvino, Ester

AU - Previati, Maurizio

AU - Nickoloff, Brian J.

AU - Croce, Carlo M.

AU - Volinia, Stefano

PY - 2018/3/9

Y1 - 2018/3/9

N2 - Cutaneous melanoma (CM) is a malignancy with increasing occurrence. Its microRNA repertoire has been defined in a number studies, leading to candidates for biological and clinical relevance: miR-200a/b/c, miR-203, miR-205, miR-204, miR-211, miR-23b and miR-26a/b. Our work was aimed to validate the role of these candidate miRNAs in melanoma, using additional patients cohorts and in vitro cultures. miR-26a, miR-204 and miR-211 were more expressed in normal melanocytes, while miR-23b, miR-200b/c, miR-203 and miR-205 in epidermis and keratinocytes. None of the keratinocyte-related miRNAs was associated with any known mutation or with clinical covariates in melanoma. On the other hand, the loss of miR-204 was enriched in melanomas with NRAS sole mutation (Fisher exact test, P = 0.001, Log Odds = 1.67), and less frequent than expected in those harbouring CDKN2A mutations (Fisher exact test, P = 0.001, Log Odds - 1.09). Additionally, miR-204 was associated with better prognosis in two independent melanoma cohorts and its exogenous expression led to growth impairment in melanoma cell lines. Thus, miR-204 represents a relevant mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in cooperation with NRAS.

AB - Cutaneous melanoma (CM) is a malignancy with increasing occurrence. Its microRNA repertoire has been defined in a number studies, leading to candidates for biological and clinical relevance: miR-200a/b/c, miR-203, miR-205, miR-204, miR-211, miR-23b and miR-26a/b. Our work was aimed to validate the role of these candidate miRNAs in melanoma, using additional patients cohorts and in vitro cultures. miR-26a, miR-204 and miR-211 were more expressed in normal melanocytes, while miR-23b, miR-200b/c, miR-203 and miR-205 in epidermis and keratinocytes. None of the keratinocyte-related miRNAs was associated with any known mutation or with clinical covariates in melanoma. On the other hand, the loss of miR-204 was enriched in melanomas with NRAS sole mutation (Fisher exact test, P = 0.001, Log Odds = 1.67), and less frequent than expected in those harbouring CDKN2A mutations (Fisher exact test, P = 0.001, Log Odds - 1.09). Additionally, miR-204 was associated with better prognosis in two independent melanoma cohorts and its exogenous expression led to growth impairment in melanoma cell lines. Thus, miR-204 represents a relevant mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in cooperation with NRAS.

KW - BRAF

KW - Breslow

KW - CDKN2A

KW - Keratinocyte

KW - Melanocyte

KW - Melanoma

KW - MicroRNA

KW - Non coding rna

KW - NRAS

KW - Somatic alterations

UR - http://www.scopus.com/inward/record.url?scp=85043479974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043479974&partnerID=8YFLogxK

U2 - 10.1186/s12943-018-0819-8

DO - 10.1186/s12943-018-0819-8

M3 - Letter

VL - 17

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 71

ER -